© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
June 18th 2021, 1:00pm
One expert tells patients to ‘hang tight’ as immunotherapy options are getting better each year.
June 14th 2021, 6:00pm
These findings, according to one of the study’s authors, demonstrate that Yescarta addresses an important unmet medical need for patients with relapsed/refractory follicular lymphoma.
June 10th 2021, 3:00pm
In this episode of the “CURE® Talks Cancer” podcast, author Steve Kelley shares both the painful and positive moments of his journey with a rare cancer.
June 6th 2021, 2:00pm
Treatment with the combination of Polivy, rituximab and lenalidomide safely conferred responses in patients with relapsed/refractory diffuse large B-cell lymphoma, with most patients still in remission at the study’s cutoff date.
June 3rd 2021, 9:00pm
Combination therapy with Aliqopa and rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma.
May 27th 2021, 9:00pm
As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.
May 27th 2021, 1:00pm
For patients with early-stage, unfavorable-risk Hodgkin lymphoma, this treatment option may allow for the reduction or elimination of radiotherapy in patients without malignant disease.
April 23rd 2021, 7:16pm
The FDA has approved Zynlonta (loncastuximab tesirine-lpyl) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
April 23rd 2021, 3:00pm
From a college student who survived lymphoma biking 4,000 miles for charity to the death of “Harry Potter” actress Helen McCrory, here’s what’s happening in the cancer landscape this week.
April 19th 2021, 9:00pm
Median progression-free survival in patients treated with Keytruda was 13.2 months versus 8.3 months with Adcetris, which makes Keytruda an “effective treatment option” for patients in this population who were either ineligible for or relapsed after autologous hematopoietic stem cell transplantation.
Adding Darzalex to Standard of Care May Improve Survival in Newly Diagnosed Multiple Myeloma
A ‘Turning Point’ for Metastatic NSCLC Treatment
My Daughter, the Learning Opportunity
Expert Breaks Down Misconceptions About COVID-19 Vaccine